United States: FDA Off-Label Promotion Memo Should Affect §510k Preemption & Evidence

Last Updated: February 6 2017
Article by James Beck

Remember how Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996), dismissed the §510k "substantially equivalence" medical device clearance as non-preemptive because it was supposedly "focused on equivalence, not safety"? Id. at 493. In the same vein:

"[S]ubstantial equivalence determinations provide little protection to the public. These determinations simply compare a post − 1976 device to a pre − 1976 device to ascertain whether the later device is no more dangerous and no less effective than the earlier device. If the earlier device poses a severe risk or is ineffective, then the later device may also be risky or ineffective."

Id. (quoting from pro-plaintiff law review article).

Most of our readers know that this characterization, assuming it was true for the 1980s-era (implanted 1987) device that the Court considered in Lohr, was no longer true, even at the time Lohr was decided, and certainly hasn't been the case since the FDAAA was passed a year after Lohr was decided. Still, this anachronistic view of §510k has flourished for twenty years, affecting first preemption and now (thanks mostly to Mesh MDL rulings) admissibility of evidence.

That's why we were interested in what the FDA had to say about today's §510k clearance process in its recent memorandum entitled "Public Health Interests and First Amendment Considerations Related to Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products," which is available here. One of our guest bloggers, Liz Minerd, recently discussed the First Amendment aspects of that document, here.

However, Appendix A to that memorandum contains the FDA's current view of the nature of §510k clearance, and we think it could come in handy with respect to debunking the out-of-date discussion in Lohr. (Note: Lohr is also impaired in that it relied heavily, 518 U.S. 485, 494, on the presumption against preemption, which as we discussed here, has since been abolished in express preemption situations such as this). Here's what – according to the FDA, and not some pro-plaintiff commentator – §510k clearance is all about in 2017:

The type of premarket review pathway is determined by the degree of review and regulation that FDA deems necessary to provide a reasonable assurance of safety and effectiveness for a given device type. Although the premarket submission review pathways (e.g., approval application (PMA), de novo, and 510(k)) differ in various ways, they all fit within the same regulatory framework that enables FDA to ensure that devices on the market are ones that have been determined by FDA to have a reasonable assurance of safety and effectiveness for each and every use for which they are intended.

Memorandum at 40 (emphasis added). In particular, since 1990, "Congress . . . required FDA to evaluate whether a new device is as safe and effective as a predicate device." Id. at at 44 n.137 (discussing Safe Medical Devices Act of 1990) (emphasis added).

In clearing devices under §510k, the FDA does not distinguish between device classifications (I, II, or III) with respect to devices being safe and effective – all devices must be, regardless of classification:

Classification determinations must be based on an evaluation of the safety and effectiveness of the device considering (1) the persons for whose use the device is intended; (2) the intended conditions of use prescribed, recommended, or suggested in the labeling of the device; and (3) the probable benefits of the device as compared with the probable risks of its use.

Id. at 41 (footnote omitted) (emphasis added). In particular, "Class II devices are devices for which general controls, by themselves, are insufficient to provide reasonable assurance of the safety and effectiveness of the device, and for which there is sufficient information to establish special controls necessary to provide such assurance." Id. at 41 n.122 (citation omitted) (emphasis added). Thus, clearance of Class II devices is, contrary to Lohr's anachronistic statements, governed by "safety and effectiveness" criteria.

Specifically, as to §510k, while the "standard is comparative," review is intended to assure device safety and effectiveness:

The 510(k) review standard is comparative, whereas the PMA and de novo review standards rely on an independent demonstration of safety and effectiveness. Nonetheless, the principles of safety and effectiveness underlie the substantial equivalence determination in every 510(k) review.

Memorandum at 42-43 (emphasis added). We repeat: "every 510k review" is conducted in accordance with with "principles of safety and effectiveness." That's the FDA speaking in 2017.

During the 510(k) review, FDA considers the device's safety and effectiveness in its substantial equivalence determination (as discussed more fully below), and also in its evaluation of compliance with any applicable special controls, which FDA has determined to be necessary to provide a reasonable assurance of safety and effectiveness for the device type.

Id. at 43 (emphasis added).

Although the 510(k) process involves a comparison of a new device to a predicate device rather than an independent demonstration of the new device's safety and effectiveness . . ., in all these cases FDA's review process reflects a determination of the level of control necessary to provide a "reasonable assurance of safety and effectiveness."

Id. at 44-45 (emphasis added).

Indeed, the FDA explains how "safety and effectiveness" are addressed in two ways during the §510k clearance process. "First, FDA must find that the intended use of the device and its predicate are "the same." Id. at 44. "Second, when comparing a new device to a predicate device, FDA must find that the two devices have the same technological characteristics," or that any "change" "does not raise different questions of safety and effectiveness." Id. at 45. As to the first stage:

FDA determines the indications for use of the new device based upon review of the proposed labeling, and then may rely upon relevant clinical or scientific information that does not appear in the proposed labeling submitted with the 510(k) regarding the safety and effectiveness of the new indications for use.

Id. at 44-45 (footnote omitted) (emphasis added). This "information" may include "clinical data" of many types that constitutes "valid scientific evidence." Id. at 45 (listing types of acceptable studies). As to the second stage:

When evaluating whether a new device is as safe and effective as a predicate device, if the risks associated with the new device increase as compared to the predicate device . . ., FDA may still determine that the new device is substantially equivalent to the predicate device if . . . there are also increased benefits with the new device as compared to the predicate device. When looking at the increased risks posed by the new device, FDA may consider the degree of risk in comparison to the predicate device. FDA may also consider whether additional measures may help mitigate the increased risks.

Id. at 45 (footnotes omitted) (emphasis added).

Thus, as the FDA's current description of the §510k process demonstrates, a lot of attention is paid to "safety and effectiveness" during the course of this type of product evaluation. Whether or not the United States Supreme Court was wrong in Lohr's description of the §510k process applicable to a 1987 device, its characterizations are demonstrably in error if asserted against the currently applicable §510k process described by the FDA earlier this month. The FDA's regulatory world has not been static over the past quarter century. Likewise, where court precedent has been superseded by events, it needs to change to reflect current realities.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
James Beck
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.